{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:55:15Z","timestamp":1769856915228,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T00:00:00Z","timestamp":1404259200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s11523-014-0326-9","type":"journal-article","created":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T18:45:24Z","timestamp":1404240324000},"page":"135-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Erlotinib in combination with pemetrexed\/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure"],"prefix":"10.1007","volume":"10","author":[{"given":"Haihong","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhua","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,2]]},"reference":[{"issue":"4","key":"326_CR1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.coc.0000158438.79665.bb","volume":"28","author":"LJ Hazard","year":"2005","unstructured":"Hazard LJ, Jensen RL, Shrieve DC (2005) Role of stereotactic radiosurgery in the treatment of brain metastases. Am J Clin Oncol 28(4):403\u2013410","journal-title":"Am J Clin Oncol"},{"key":"326_CR2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000331188","volume":"25","author":"T Kawabe","year":"2012","unstructured":"Kawabe T, Phi JH, Yamamoto M, Kim DG, Barfod BE, Urakawa Y (2012) Treatment of brain metastasis from lung cancer. Prog Neurol Surg 25:148\u2013155","journal-title":"Prog Neurol Surg"},{"key":"326_CR3","unstructured":"Song Z, Yu X, He C, Zhang B, Zhang Y (2013) Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer. J Thorac Dis 5(4):400\u2013405"},{"issue":"3","key":"326_CR4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1183\/09031936.00195609","volume":"37","author":"R Porta","year":"2011","unstructured":"Porta R, S\u00e1nchez-Torres JM, Paz-Ares L, Massut\u00ed B, Reguart N, Mayo C, Lianes P, Queralt C, Guillem V, Salinas P, Catot S, Isla D, Pradas A, G\u00farpide A, de Castro J, Polo E, Puig T, Tar\u00f3n M, Colomer R, Rosell R (2011) Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 37(3):624\u2013631","journal-title":"Eur Respir J"},{"issue":"4","key":"326_CR5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/neuonc\/nos004","volume":"14","author":"O Bailon","year":"2012","unstructured":"Bailon O, Chouahnia K, Augier A, Bouillet T, Billot S, Coman I, Ursu R, Belin C, Zelek L, Des Guetz G, Levy C, Carpentier AF (2012) Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro Oncol 14(4):491\u2013495","journal-title":"Neuro Oncol"},{"issue":"9","key":"326_CR6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1742-1241.2005.00622.x","volume":"59","author":"J Spicer","year":"2005","unstructured":"Spicer J, Harper P (2005) Targeted therapies for non-small cell lung cancer. Int J Clin Pract 59(9):1055\u20131062","journal-title":"Int J Clin Pract"},{"issue":"11","key":"326_CR7","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1093\/annonc\/mdq246","volume":"21","author":"M Ranson","year":"2010","unstructured":"Ranson M, Reck M, Anthoney A, Hanauske AR, Dean E, Melezinek I, Klingelschmitt G, Kletzl H, Blatter J, Twelves C (2010) Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. Ann Oncol 21(11):2233\u20132239","journal-title":"Ann Oncol"},{"key":"326_CR8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/1471-2407-12-296","volume":"12","author":"S Minami","year":"2012","unstructured":"Minami S, Kijima T, Takahashi R, Kida H, Nakatani T, Hamaguchi M, Takeuchi Y, Nagatomo I, Yamamoto S, Tachibana I, Komuta K, Kawase I (2012) Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study. BMC Cancer 12:296","journal-title":"BMC Cancer"},{"issue":"2","key":"326_CR9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"4","key":"326_CR10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/annonc\/mds529","volume":"24","author":"YL Wu","year":"2013","unstructured":"Wu YL, Zhou C, Cheng Y, Lu S, Chen GY, Huang C, Huang YS, Yan HH, Ren S, Liu Y, Yang JJ (2013) Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol 24(4):993\u2013999","journal-title":"Ann Oncol"},{"issue":"1","key":"326_CR11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.lungcan.2008.10.016","volume":"65","author":"HG Yi","year":"2009","unstructured":"Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ (2009) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65(1):80\u201384","journal-title":"Lung Cancer"},{"issue":"11","key":"326_CR12","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/JTO.0b013e3181b62572","volume":"4","author":"T Katayama","year":"2009","unstructured":"Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, Hatooka S, Sueda T, Hida T, Yatabe Y, Mitsudomi T (2009) Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 4(11):1415\u20131419","journal-title":"J Thorac Oncol"},{"issue":"12","key":"326_CR13","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","volume":"13","author":"C Grommes","year":"2011","unstructured":"Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB (2011) \u201cPulsatile\u201d high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 13(12):1364\u20131369","journal-title":"Neuro Oncol"},{"issue":"3","key":"326_CR14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","volume":"70","author":"Y Togashi","year":"2012","unstructured":"Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, Sakamori Y, Nagai H, Kim YH, Katsura T, Mishima M (2012) Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 70(3):399\u2013405","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"326_CR15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11060-010-0128-6","volume":"99","author":"JL Clarke","year":"2010","unstructured":"Clarke JL, Pao W, Wu N, Miller VA, Lassman AB (2010) High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99(2):283\u2013286","journal-title":"J Neurooncol"},{"issue":"1\u20132","key":"326_CR16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000335736","volume":"35","author":"H Saito","year":"2012","unstructured":"Saito H, Murakami S, Kondo T, Oshita F, Noda K, Yamada K (2012) Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months. Onkologie 35(1\u20132):18\u201322","journal-title":"Onkologie"},{"issue":"2","key":"326_CR17","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.lungcan.2011.03.010","volume":"74","author":"A Hata","year":"2011","unstructured":"Hata A, Katakami N, Yoshioka H, Fujita S, Kunimasa K, Nanjo S, Otsuka K, Kaji R, Tomii K, Iwasaku M, Nishiyama A, Hayashi H, Morita S, Ishida T (2011) Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer 74(2):268\u2013273","journal-title":"Lung Cancer"},{"issue":"11","key":"326_CR18","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/1078-0432.CCR-06-2923","volume":"13","author":"T Li","year":"2007","unstructured":"Li T, Ling YH, Goldman ID, Perez-Soler R (2007) Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 13(11):3413\u20133422","journal-title":"Clin Cancer Res"},{"issue":"4","key":"326_CR19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00280-006-0285-7","volume":"59","author":"SL Stapleton","year":"2007","unstructured":"Stapleton SL, Reid JM, Thompson PA, Ames MM, McGovern RM, McGuffey L, Nuchtern J, Dauser R, Blaney SM (2007) Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother Pharmacol 59(4):461\u2013466","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-014-0326-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-014-0326-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-014-0326-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T12:15:13Z","timestamp":1559391313000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-014-0326-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,2]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["326"],"URL":"https:\/\/doi.org\/10.1007\/s11523-014-0326-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,2]]}}}